<code id='36CDF5DCAD'></code><style id='36CDF5DCAD'></style>
    • <acronym id='36CDF5DCAD'></acronym>
      <center id='36CDF5DCAD'><center id='36CDF5DCAD'><tfoot id='36CDF5DCAD'></tfoot></center><abbr id='36CDF5DCAD'><dir id='36CDF5DCAD'><tfoot id='36CDF5DCAD'></tfoot><noframes id='36CDF5DCAD'>

    • <optgroup id='36CDF5DCAD'><strike id='36CDF5DCAD'><sup id='36CDF5DCAD'></sup></strike><code id='36CDF5DCAD'></code></optgroup>
        1. <b id='36CDF5DCAD'><label id='36CDF5DCAD'><select id='36CDF5DCAD'><dt id='36CDF5DCAD'><span id='36CDF5DCAD'></span></dt></select></label></b><u id='36CDF5DCAD'></u>
          <i id='36CDF5DCAD'><strike id='36CDF5DCAD'><tt id='36CDF5DCAD'><pre id='36CDF5DCAD'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:knowledge    - browse:6514

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time